The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001).
 
Amita Patnaik
Honoraria - Texas Society of Clinical Oncology (TxSCO)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (I); Daiichi Sankyo, Inc.; Genentech/Roche (I); Gilead Sciences; HalioDx; Ionova; Janssen; Merck; MERCK (I); Novartis; Seagen; Silverback Therapeutics
Research Funding - 1200 Pharma (Inst); AADi (Inst); Abbvie (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arcus Ventures (Inst); Astellas Pharma (Inst); Bolt Biotherapeutics (Inst); Carrick Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi-Sankyo (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Institut de Recherches Internationales Servier (I.R.I.S) (Inst); Ionova (Inst); Ionova (Inst); Klus Pharma (Inst); KSQ Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo@Lilly (Inst); Merck (Inst); Nektar (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Pyrotec Therapeutics (Inst); Quanta Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst)
 
Nilofer Saba Azad
Stock and Other Ownership Interests - Haystack Oncology; Irazu; Tempus
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; Taiho Pharmaceutical; Tempus
Speakers' Bureau - AstraZeneca
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); AtlasMedx (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); EMD Serono (Inst); Genentech (Inst); Incyte (Inst); Intensity Therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Mitesh J. Borad
Consulting or Advisory Role - BJ Bioscience; Genentech; Imvax; Kriya Therapeutics; Lynx Group; Merck; Senti Biosciences; Tempus; Zymeworks
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Basilea (Inst); Biond Biologics (Inst); Celgene (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Merck Serono (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Qurient (Inst); RedHill Biopharma (Inst); Relay Therapeutics (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Taiho Pharmaceutical (Inst); ZielBio (Inst)
 
Andrea J. Bullock
Stock and Other Ownership Interests - Medtronic
Consulting or Advisory Role - Agenus; Oncolytics; Sirtex Medical
Research Funding - Agenus (Inst); AstraZeneca (Inst); Geistlich Pharma (Inst); Ipsen (Inst); Oncomatryx (Inst); Panova (Inst)
Travel, Accommodations, Expenses - Agenus
 
Justin A Call
No Relationships to Disclose
 
S. Lindsey Davis
Stock and Other Ownership Interests - Johnson & Johnson/MedTech
Speakers' Bureau - Allergan (I)
Research Funding - Boston Scientific (I); Bristol-Myers Squibb (Inst); EMD Serono (Inst); I-Mab (Inst); Merck (Inst); ORIC Pharmaceuticals (Inst); Symphogen (Inst); TriSalus Life Sciences (Inst); Tvardi Therapeutics (Inst)
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Bayer; BMS; Eisai; Merck; Mirati Therapeutics; Pfizer; Roche/Genentech; Taiho Pharmaceutical
Research Funding - Agenus (Inst); Roche/Genentech (Inst); Verastem (Inst)
 
Rachel Anne Goodwin
Honoraria - Advanced Accelerator Applications; Eisai; Incyte; Incyte; Ipsen; Merck; Pfizer
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Amgen; Apobiologix; Astellas Pharma; AstraZeneca Canada; Bayer; Eisai; Incyte; Ipsen; Merck; MSD; Novartis; Pfizer; Roche Canada; Taiho Pharmaceutical; Viatris
Speakers' Bureau - Amgen; Bayer; Bayer; Eisai; Ipsen; Merck; Mylan; Pfizer
Research Funding - Eisai; Ipsen
Travel, Accommodations, Expenses - Ipsen; Novartis; Pfizer
 
Nehal J. Lakhani
Research Funding - Alexo Therapeutics (Inst); Alkermes (Inst); Alkermes/Mural Oncology (Inst); Alpine Immune Sciences (Inst); Alpine Immune Sciences (Inst); Apexian Pharmaceuticals (Inst); Arcus Ventures (Inst); Artios (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech SE (Inst); Biosplice (Inst); Celgene (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Epizyme (Inst); Forty Seven (Inst); Genmab (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Janssen (Inst); Jounce Therapeutics (Inst); KSQ Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Sapience Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Servier (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - Arcus Biosciences (Inst); AstraZeneca (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Elevation Oncology (Inst); EMD Serono (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst)
Research Funding - 1200 Pharma (Inst); Actuate Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); IMPAC Medical Systems (Inst); Leap Therapeutics (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)
 
Cesar Augusto Perez
Consulting or Advisory Role - BeiGene; EMD Serono
Research Funding - Accutar Biotech (Inst); ADANATE Biotechnology (Inst); Artios (Inst); Ayala Pharmaceuticals (Inst); Elevation Oncology; Elpiscience (Inst); Genentech; Hyamab (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); Merus; Mirati Therapeutics (Inst); Relay Therapeutics (Inst); Ribon Therapeutics (Inst); Seagen (Inst); Tachyon Therapeutics; Tallac Therapeutics (Inst); Xilio Therapeutics (Inst); Zhuhai Yufan Biotechnologies (Inst)
 
Pourya Pourhosseini
Employment - Pfizer; Pfizer; Seagen
Stock and Other Ownership Interests - Seagen
Travel, Accommodations, Expenses - Seagen
 
Tianhua Wang
Employment - Pfizer; Seagen
Stock and Other Ownership Interests - Seagen
 
Brigitte Demers
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
Patents, Royalties, Other Intellectual Property - Sanofi
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dava Oncology
Consulting or Advisory Role - Abbvie; AstraZeneca; Black Diamond Therapeutics; Calibr; Daiichi Sankyo/Astra Zeneca; EcoR1 Capital; Eisai; Exelixis; GT Aperion; Incyte; Infinity Pharmaceuticals; Karyopharm Therapeutics; LegoChem Biosciences; Lengo Therapeutics; Menarini Group; OnCusp Therapeutics; Protai; Seagen; Tallac Therapeutics; Theratechnologies; Zentalis; Zymeworks
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ARTIDIS; Cholangiocarcinoma Foundation; Dava Oncology; ESMO; European Organisation for Research and Treatment of Cancer (EORTC)